Bio-Rad Life Sciences Q2 Revenues Drop 4 Percent; Digital PCR Sales Slower than Anticipated | GenomeWeb

Bio-Rad this week reported a 4 percent drop in second-quarter revenues for its Life Sciences segment, which includes its traditional endpoint and real-time PCR products as well as its digital PCR products acquired last year along with QuantaLife.

The company recorded a profit of $48.3 million, or $1.69 per share, in Q2 2012 compared to a profit of $40 million, or $1.41 per share in the year-ago period.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.

Mar
02
Sponsored by
VelaDx

This online seminar will highlight recent advances in the use of next-generation sequencing to detect drug-resistant mutations in patients with HIV or HCV.